Biotech Takes It on the Chin in May

PR Newswire (press release) - New York,NY,USA
... Biogen Idec and Fumapharm AG announced positive results from a Phase II study designed to evaluate the efficacy and safety of BG-12, an oral fumarate, in patients with relapsing-remitting multiple sclerosis (MS).